Scribe Therapeutics, Inc. (SCTX)
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Scribe Therapeutics Inc.
NASDAQ:SCTXHealthcare · Biotechnology
-14.23%$15.40
AH Close$15.40+0.00%vs close
AH Close$15.40+0.00%vs close
Mkt Cap$291.64M
Float12.04M
O/S18.93M
Inst Own0.0%
SI20.5%
Dilution
Delisting Issues Timeline
Financials Summary
No financial data available.
Debt & Equity
No debt & equity data available.
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in SCTX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
No balance sheet details available.
Income Statement
No income statement data available.
Balance Sheet
No balance sheet data available.
Cash Flow Statement
No cash flow data available.